Otwarty dostęp

CEACAM1 - A Promising Biomarker for Melanoma


Zacytuj

1. Helfrich I, Singer B. Size Matters: The Functional Role of the CEACAM1 Isoform Signature and Its Impact for NK Cell-Mediated Killing in Melanoma. Cancers. 2019;11:356. https://doi.org/10.3390/cancers11030356.10.3390/cancers11030356 Search in Google Scholar

2. Davey MG, Miller N, McInerney NM. A Review of Epidemiology and Cancer Biology of Malignant Melanoma. Cureus; 2021. https://doi.org/10.7759/cureus.15087.10.7759/cureus.15087 Search in Google Scholar

3. Turcu G, Nedelcu RI, Ion DA, Brînzea A, Cioplea MD, 11Jilaveanu LB, et al. CEACAM1: Expression and Role in Melanocyte Transformation. Disease Markers. 2016;2016:1–8. https://doi.org/10.1155/2016/9406319.10.1155/2016/9406319 Search in Google Scholar

4. Dinehart MS, Dinehart SM, Sukpraprut-Braaten S, High WA. Immunohistochemistry utilization in the diagnosis of melanoma. Journal of Cutaneous Pathology. 2020;47:446–50. https://doi.org/10.1111/cup.13648.10.1111/cup.13648 Search in Google Scholar

5. Sivan S, Suzan F, Rona O, Tamar H, Vivian B, Tamar P, et al. Serum CEACAM1 Correlates with Disease Progression and Survival in Malignant Melanoma Patients. Clinical and Developmental Immunology. 2012;2012:1–8. https://doi.org/10.1155/2012/290536.10.1155/2012/290536 Search in Google Scholar

6. Kluger HM, Hoyt K, Bacchiocchi A, Mayer T, Kirsch J, Kluger Y, et al. Plasma Markers for Identifying Patients with Metastatic Melanoma. Clinical Cancer Research. 2011;17:2417–25. https://doi.org/10.1158/1078-0432.ccr-10-2402.10.1158/1078-0432.CCR-10-2402 Search in Google Scholar

7. de Wit NJW, van Muijen GNP, Ruiter DJ. Immunohistochemistry in melanocytic proliferative lesions. Histopathology. 2004;44:517–41. https://doi.org/10.1111/j.1365-2559.2004.01860.x.10.1111/j.1365-2559.2004.01860.x Search in Google Scholar

8. Torres-Cabala C, Li-Ning-Tapia E, Hwu W-J. Pathology-based Biomarkers Useful for Clinical Decisions in Melanoma. Archives of Medical Research. 2020;51:827–38. https://doi.org/10.1016/j.arcmed.2020.09.008.10.1016/j.arcmed.2020.09.008 Search in Google Scholar

9. Khatib N, Pe’er J, Ortenberg R, Schachter J, Frenkel S, Markel G, et al. Carcinoembryonic Antigen Cell Adhesion Molecule-1 (CEACAM1) in Posterior Uveal Melanoma: Correlation with Clinical and Histological Survival Markers. Investigative Opthalmology & Visual Science. 2011;52:9368. https://doi.org/10.1167/iovs.10-6006.10.1167/iovs.10-6006 Search in Google Scholar

10. Calinescu A, Turcu G, Nedelcu RI, Brinzea A, Hodorogea A, Antohe M, et al. On the Dual Role of Carcinoembryonic Antigen-Related Cell Adhesion Molecule 1 (CEACAM1) in Human Malignancies. Journal of Immunology Research. 2018;2018:1–8. https://doi.org/10.1155/2018/7169081.10.1155/2018/7169081 Search in Google Scholar

11. Ortenberg R, Sapoznik S, Zippel D, Shapira-Frommer R, Itzhaki O, Kubi A, et al. Serum CEACAM1 Elevation Correlates with Melanoma Progression and Failure to Respond to Adoptive Cell Transfer Immunotherapy. Journal of Immunology Research. 2015;2015:1–8. https://doi.org/10.1155/2015/902137.10.1155/2015/902137 Search in Google Scholar

12. Beauchemin N, Arabzadeh A. Carcinoembryonic antigen-related cell adhesion molecules (CEACAMs) in cancer progression and metastasis. Cancer and Metastasis Reviews. 2013;32:643–71. https://doi.org/10.1007/s10555-013-9444-6.10.1007/s10555-013-9444-6 Search in Google Scholar

13. Sapoznik S, Ortenberg R, Schachter J r, Markel G. CEACAM1 in Malignant Melanoma: A Diagnostic and Therapeutic Target. Current Topics in Medicinal Chemistry. 2012;12:3–10. https://doi.org/10.2174/156802612798919259.10.2174/156802612798919259 Search in Google Scholar

14. Ebrahimnejad A, Streichert T, Nollau P, Horst AK, Wagener C, Bamberger A-M, et al. CEACAM1 Enhances Invasion and Migration of Melanocytic and Melanoma Cells. The American Journal of Pathology. 2004;165:1781–7. https://doi.org/10.1016/s0002-9440(10)63433-5.10.1016/S0002-9440(10)63433-5 Search in Google Scholar

15. Ullrich N, Heinemann A, Nilewski E, Scheffrahn I, Klode J, Scherag A, et al. CEACAM1-3S Drives Melanoma Cells into NK Cell-Mediated Cytolysis and Enhances Patient Survival. Cancer Research. 2015;75:1897–907. https://doi.org/10.1158/0008-5472.can-14-1752.10.1158/0008-5472.CAN-14-1752 Search in Google Scholar

16. Horst AK, Wagener C. CEA-Related CAMs. Handbook of Experimental Pharmacology. 2004:283–341. https://doi.org/10.1007/978-3-540-68170-0_10.10.1007/978-3-540-68170-0_10 Search in Google Scholar

17. Kilic N, Oliveira-Ferrer L, Wurmbach J-H, Loges S, Chalajour F, Vahid SN, et al. Pro-angiogenic Signaling by the Endothelial Presence of CEACAM1. Journal of Biological Chemistry. 2005;280:2361–9. https://doi.org/10.1074/jbc.m409407200.10.1074/jbc.M409407200 Search in Google Scholar

18. Bramswig KH, Poettler M, Unseld M, Wrba F, Uhrin P, Zimmermann W, et al. Soluble Carcinoembryonic Antigen Activates Endothelial Cells and Tumor Angiogenesis. Cancer Research. 2013;73:6584–96. https://doi.org/10.1158/0008-5472.can-13-0123.10.1158/0008-5472.CAN-13-0123 Search in Google Scholar

19. Kuespert K, Pils S, Hauck CR. CEACAMs: their role in physiology and pathophysiology. Current Opinion in Cell Biology. 2006;18:565–71. https://doi.org/10.1016/j.ceb.2006.08.008.10.1016/j.ceb.2006.08.008 Search in Google Scholar

20. Kfir-Elirachman K, Ortenberg R, Vizel B, Besser MJ, Barshack I, Schachter J, et al. Regulation of CEACAM1 Protein Expression by the Transcription Factor ETS-1 in BRAF-Mutant Human Metastatic Melanoma Cells. Neoplasia. 2018;20:401–9. https://doi.org/10.1016/j.neo.2018.01.012.10.1016/j.neo.2018.01.012 Search in Google Scholar

21. Ashkenazi S, Ortenberg R, Besser M, Schachter J, Markel G. SOX9 indirectly regulates CEACAM1 expression and immune resistance in melanoma cells. Oncotarget. 2016;7:30166–77. https://doi.org/10.18632/oncotarget.7379.10.18632/oncotarget.7379 Search in Google Scholar

22. Magee MS, Snook AE, Marszalowicz GP, Waldman SA. Immunotherapeutic strategies to target prognostic and predictive markers of cancer. Biomarkers in Medicine. 2013;7:23–35. https://doi.org/10.2217/bmm.12.110.10.2217/bmm.12.110 Search in Google Scholar

eISSN:
2285-7079
Język:
Angielski
Częstotliwość wydawania:
4 razy w roku
Dziedziny czasopisma:
Medicine, Assistive Professions, Nursing, Basic Medical Science, other, Clinical Medicine